Fluciclovine PET/CT scan for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of multiple myeloma meeting specific criteria (like certain blood or bone marrow findings).
- You must have measurable disease, like abnormal proteins in the blood or urine, or a visible lesion on a scan.
- You can be either newly diagnosed or have myeloma that has relapsed or not responded to at least one prior treatment.
- You must be 18 years or older and able to undergo a PET/CT scan.
- You cannot have a history of allergic reaction to the imaging agent, severe claustrophobia, or uncontrolled illness.
- Women who can become pregnant must have a negative pregnancy test and use contraception; breastfeeding must stop during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.